Stage 4 Lung Cancer: What Now?

This page is for people newly told they have stage 4 non-small cell lung cancer, and for those close to them. It explains what the stage means, which test results shape the plan, how to read survival numbers, and when to get help fast.

The AJCC staging manual, reprinted in NCI's clinician summary, splits metastatic lung cancer by an M descriptor.

• M1a means the cancer has stayed inside the chest: separate nodules in the opposite lung, nodules on the pleura (lining of the lung) or pericardium (sac around the heart), or fluid around the lung or heart that contains cancer cells.
• M1b means one deposit in one organ outside the chest, which can include a single distant lymph node.
• M1c means several deposits, in one organ or in more than one.

Stage IVA covers M1a and M1b. Stage IVB covers M1c. That distinction changes how aggressively local treatment is considered, so it is worth asking which letter is on your report.

One detail is easy to miss. NCI notes that if repeated microscope checks of the pleural fluid find no cancer cells, and the fluid is neither bloody nor an exudate (a protein-rich fluid from inflammation), the effusion can be left out of staging entirely. A person told they are stage 4 because of fluid should ask whether the fluid was actually tested.

Two results drive everything: the exact tumor type under the microscope, and the molecular profile.

NCI puts adenocarcinoma at about 40% of lung cancers, squamous cell carcinoma at about 25%, and large cell carcinoma at about 10%. The subtype decides which chemotherapy drugs are even usable. Pemetrexed, for example, is used in nonsquamous disease.

On the molecular side, NCI lists genes that can be matched to approved drugs or drugs in development: EGFR, ALK, BRAF, ROS1, RET, NTRK1, NTRK2, NTRK3, MET, KRAS, and HER2. Frequencies vary widely. In a series of 2,142 lung adenocarcinomas, EGFR exon 19 deletions or the L858R change appeared in 52% of never-smokers, 15% of former smokers, and 6% of current smokers. ALK::EML4 fusions occur in 3% to 7% of unselected non-small cell lung cancer (NSCLC) cases. NCI does not give frequencies for the other genes on that list, so ask your team how common yours is. EGFR mutation in lung cancer explains what those reports look like.

Two imaging cautions matter here. FDG-PET, the scan that lights up active tumor, is not reliable for brain or urinary tract deposits, because the tracer collects in both places normally. Standard PET scans may also stop at the pelvis. Brain MRI finds more than CT does. In one randomized comparison before lung surgery, hidden brain metastases turned up in 4% of stage I and II cases but 11.4% of stage III cases.

Two federal sources give different figures, and the gap is instructive.

SEER's Cancer Stat Facts page, using cases from 2016 to 2022, reports that 51% of lung and bronchus cancers are already distant at diagnosis, with a 5-year relative survival of 10.5% for that group and 29.5% across all stages. NCI's clinician summary, using 2014 to 2020 data, gives 9% for distant disease and 27% overall.

Neither is wrong. They cover different years. The SEER page uses the newer window, and its numbers are slightly higher, which fits a period when targeted drugs and immunotherapy were spreading. Both still describe people diagnosed years ago. Neither can account for a treatment approved last year, and neither knows your tumor's molecular profile. What metastatic cancer means covers how these statistics are built.

If a matched genetic alteration is found, an oral targeted drug is usually the opening move rather than chemotherapy.

If no driver is found, PD-L1 level and tumor subtype guide the choice between immunotherapy alone and immunotherapy combined with chemotherapy. Getting the molecular result before the first infusion is not a delay, it is the point.

Waiting is uncomfortable. Tissue testing takes time, and turnaround varies between labs, so ask your team for their expected date.

The first is symptom control: shrinking a tumor that is blocking an airway, causing bleeding, or eroding into bone. Courses are short.

The second is treating the brain. Brain deposits are common in lung cancer, and NCI notes that preventive whole-brain radiation lowers how often brain metastases appear but has not been shown to lengthen survival, with unknown effects on quality of life. That tradeoff belongs in an explicit conversation. Lung cancer treatment by stage sets out where each modality fits.

This is one of the few supportive care questions answered by a randomized trial in metastatic non-small cell lung cancer specifically.

In a 151-person study published in the New England Journal of Medicine, people newly diagnosed with metastatic NSCLC were assigned either to standard oncology care or to standard care plus palliative care starting right away. At 12 weeks the early palliative care group scored 98.0 on the FACT-L quality of life scale versus 91.5. Depressive symptoms occurred in 16% versus 38%. Fewer received aggressive care at the end of life, 33% versus 54%. Median survival was 11.6 months versus 8.9 months.

Palliative care is not hospice and does not replace cancer treatment. Ask for the referral at diagnosis rather than at a crisis point.

• You cough up blood, more than streaks in sputum.
• Your face, neck, or an arm swells and neck veins stand out. This can mean pressure on the superior vena cava.
• You have new weakness or numbness in the legs, trouble walking, or loss of bladder or bowel control. Spinal cord compression is treated in hours, not days.
• A new headache is worst in the morning, or comes with vomiting, confusion, or a seizure.
• You are breathless while sitting still, or your resting heart rate stays above 100.

• Your temperature reaches 100.4 degrees F (38 C). MedlinePlus, reviewed October 2024, uses 100.4 F; NCI's infection page, reviewed January 2020, uses 100.5 F. Use the lower, newer number. If you cannot reach your team, go to the emergency room.

• https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq
• https://www.cancer.gov/types/lung/patient/non-small-cell-lung-treatment-pdq
• https://seer.cancer.gov/statfacts/html/lungb.html
• https://pubmed.ncbi.nlm.nih.gov/20818875/
• https://www.cancer.gov/about-cancer/treatment/side-effects/infection
• https://medlineplus.gov/ency/patientinstructions/000913.htm